<p>隨着美國股市在美聯儲決定降息後出現上漲，投資者密切關注內部持股比例高的成長型公司。在這種環境下，像 Krystal Biotech 這樣的股票，內部人士持有顯著股份，尤其具有吸引力，因為它們通常在不斷變化的經濟條件下傳達出對公司潛力的信心。</p>
<h3>美國內部持股比例高的十大成長型公司</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>內部持股比例</strong></td>
<td><strong>收益增長</strong></td>
</tr>
<tr>
<td>超微計算機 (SMCI)</td>
<td>13.9%</td>
<td>50.7%</td>
</tr>
<tr>
<td>StubHub Holdings (STUB)</td>
<td>14.2%</td>
<td>73.5%</td>
</tr>
<tr>
<td>SES AI (SES)</td>
<td>12%</td>
<td>68.9%</td>
</tr>
<tr>
<td>Niu Technologies (NIU)</td>
<td>37.2%</td>
<td>93.7%</td>
</tr>
<tr>
<td>Credo Technology Group Holding (CRDO)</td>
<td>10.4%</td>
<td>30.7%</td>
</tr>
<tr>
<td>Cloudflare (NET)</td>
<td>10.2%</td>
<td>43.5%</td>
</tr>
<tr>
<td>Bitdeer Technologies Group (BTDR)</td>
<td>33.4%</td>
<td>131.7%</td>
</tr>
<tr>
<td>Atour Lifestyle Holdings (ATAT)</td>
<td>18%</td>
<td>24.4%</td>
</tr>
<tr>
<td>Astera Labs (ALAB)</td>
<td>11.7%</td>
<td>29.0%</td>
</tr>
<tr>
<td>AppLovin (APP)</td>
<td>27.5%</td>
<td>27.3%</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們快速增長的美國內部持股比例高的公司篩選器中的 203 只股票的完整列表。</p>
<p>讓我們從我們的專業篩選器中發現一些寶藏。</p>
<h2>Krystal Biotech (KRYS)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Krystal Biotech, Inc. 是一家商業階段的生物技術公司，專注於發現、開發、製造和商業化針對美國高未滿足醫療需求疾病的基因藥物，市值為 69.5 億美元。</p>
<p><strong>運營：</strong> 該公司從其專注於基因藥物的細分市場中產生了 3.7316 億美元的收入，針對美國高未滿足醫療需求的疾病。</p>
<p><strong>內部持股比例：</strong> 10.3%</p>
<p><strong>收益增長預測：</strong> 每年 28.3%。</p>
<p>Krystal Biotech 展示了顯著的增長，收益從一年前的 2718 萬美元增加到 2025 年第三季度的 7937 萬美元。該公司正在推進其基因藥物管線，涵蓋多個領域，得到了 FDA 對其 KB801 眼藥水療法的技術平台認證的支持。儘管交易價格低於估計的公允價值，但 Krystal 的收入和收益預計將快於市場平均水平增長，儘管最近幾個月內部持股的詳細信息尚不可用。</p>
<ul>
<li>通過閲讀我們的分析師估計報告，深入瞭解 Krystal Biotech 的表現。</li>
<li>我們精心準備的 Krystal Biotech 估值報告暗示其股價可能低於預期。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0bee3c6e-0bb9-45f2-94da-e22eb8705c98/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0bee3c6e-0bb9-45f2-94da-e22eb8705c98/chart/earnings-and-revenue-growth"/></p>
<p>截至 2025 年 12 月的 KRYS 收益和收入增長</p>
<h2>凱悦酒店 (H)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> 凱悦酒店公司在美國及國際上運營，市值約為 146.9 億美元。</p>
<p><strong>運營：</strong> 凱悦的收入主要來自其自有和租賃的細分市場，收入為 12.4 億美元，其次是管理和特許經營收入為 11.9 億美元，分銷貢獻為 9.74 億美元。</p>
<p><strong>內部持股比例：</strong> 11.2%</p>
<p><strong>收益增長預測：</strong> 每年 57.5%。</p>
<p>凱悦酒店公司正處於增長階段，預計收入將以每年 17.8% 的速度增長，超過美國市場平均水平。儘管最近有內部人士出售股票，但公司受益於強大的內部持股和戰略擴張，如凱悦機場酒店。其財務狀況包括 15 億美元的循環信貸額度和最近發行的 3.9983 億美元的債券，利率為 5.4%。儘管目前尚未盈利，但預計在未來三年內收益將顯著增長。</p>
<ul>
<li>在這裏深入瞭解凱悦酒店的具體情況，查看我們的詳細增長預測報告。</li>
<li>我們的估值報告顯示凱悦酒店可能被高估。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/27434017-c144-4ad1-8d3f-aca9ae5c07f4/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/27434017-c144-4ad1-8d3f-aca9ae5c07f4/chart/earnings-and-revenue-growth"/></p>
<p>截至 2025 年 12 月的 H 收益和收入增長</p>
<h2>On Holding (ONON)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> On Holding AG 在全球開發和分銷運動產品，市值約為 162.5 億美元。</p>
<p><strong>運營：</strong> 該公司主要從其運動鞋細分市場產生收入，金額為 28.8 億瑞士法郎。</p>
<p><strong>內部持股比例：</strong> 26.3%</p>
<p><strong>收益增長預測：</strong> 每年 30.1%。</p>
<p>On Holding 正在經歷強勁增長，預計收益將以每年 30.1% 的速度增長，超過美國市場。該公司最近報告了強勁的第三季度業績，銷售額從去年同期的 6.358 億瑞士法郎上升至 7.944 億瑞士法郎，淨收入顯著改善，從 3050 萬瑞士法郎提高至 1.189 億瑞士法郎。儘管過去三個月內部交易活動仍不明朗，但 On Holding 的戰略財務舉措包括未來證券發行的貨架註冊申請。</p>
<ul>
<li>點擊探索我們在 On Holding 收益增長報告中的詳細發現。</li>
<li>根據我們的估值報告，On Holding 的股價可能偏高。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/30b460e6-f1a8-445d-9f78-310d4e375cd1/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/30b460e6-f1a8-445d-9f78-310d4e375cd1/chart/ownership-breakdown"/></p>
<p>截至 2025 年 12 月的 ONON 持股結構</p>
<h2>將想法轉化為行動</h2>
<ul>
<li>在這裏探索我們快速增長的美國內部持股比例高的公司篩選器中的 203 個名稱。</li>
<li>對其他選擇感到好奇？人工智能即將改變醫療保健。這 30 只股票正在從早期診斷到藥物發現方面進行工作。最重要的是 - 它們的市值都在 100 億美元以下 - 現在仍然有機會提前介入。</li>
</ul>
<p>這篇來自 Simply Wall St 的文章是一般性的。<strong>我們提供基於歷史數據和分析師預測的評論，僅使用無偏見的方法，我們的文章並不旨在提供財務建議。</strong> 它不構成買賣任何股票的推薦，也不考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。該分析僅考慮內部人士直接持有的股票，不包括通過其他工具如公司和/或信託實體間接持有的股票。所有預測的收入和收益增長率均以年化（每年）增長率的形式引用，時間範圍為 1-3 年。</p>
<p>用於國防和災難的移動基礎設施</p>
<p>下一波機器人技術不是類人型的。它是完全自主的塔，在 30 分鐘內提供 5G、ISR 和雷達，隨時隨地。</p>
<p>在下一輪合同之前獲取投資者簡報</p>
<p>代表 CiTech 贊助</p>

KRYS

昂跑

凱悦酒店

<p>投資者正關注內部持股比例高的成長型股票，因為在美聯儲降息後，美國股市上漲。值得注意的公司包括 Krystal Biotech、凱悦酒店和昂跑，這些公司都顯示出顯著的盈利增長和內部持股比例。Krystal Biotech 的市值為 69.5 億美元，內部持股比例為 10.3%，預計年盈利增長 28.3%。凱悦酒店的內部持股比例為 11.2%，盈利增長預測為 57.5%。昂跑的內部持股比例為 26.3%，盈利增長預測為 30.1%</p>

<p>As the U.S. stock market experiences a surge following the Federal Reserve's decision to cut interest rates, investors are closely watching growth companies with high insider ownership. In this environment, stocks like Krystal Biotech and others where insiders have significant stakes can be particularly attractive, as they often signal confidence in the company's potential amidst evolving economic conditions.</p>
<div class="lb-trans"><p>隨着美國股市在美聯儲決定降息後出現上漲，投資者密切關注內部持股比例高的成長型公司。在這種環境下，像 Krystal Biotech 這樣的股票，內部人士持有顯著股份，尤其具有吸引力，因為它們通常在不斷變化的經濟條件下傳達出對公司潛力的信心。</p>
</div><h3>Top 10 Growth Companies With High Insider Ownership In The United States</h3>
<div class="lb-trans"><h3>美國內部持股比例高的十大成長型公司</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Insider Ownership</strong></td>
<td><strong>Earnings Growth</strong></td>
</tr>
<tr>
<td>Super Micro Computer (SMCI)</td>
<td>13.9%</td>
<td>50.7%</td>
</tr>
<tr>
<td>StubHub Holdings (STUB)</td>
<td>14.2%</td>
<td>73.5%</td>
</tr>
<tr>
<td>SES AI (SES)</td>
<td>12%</td>
<td>68.9%</td>
</tr>
<tr>
<td>Niu Technologies (NIU)</td>
<td>37.2%</td>
<td>93.7%</td>
</tr>
<tr>
<td>Credo Technology Group Holding (CRDO)</td>
<td>10.4%</td>
<td>30.7%</td>
</tr>
<tr>
<td>Cloudflare (NET)</td>
<td>10.2%</td>
<td>43.5%</td>
</tr>
<tr>
<td>Bitdeer Technologies Group (BTDR)</td>
<td>33.4%</td>
<td>131.7%</td>
</tr>
<tr>
<td>Atour Lifestyle Holdings (ATAT)</td>
<td>18%</td>
<td>24.4%</td>
</tr>
<tr>
<td>Astera Labs (ALAB)</td>
<td>11.7%</td>
<td>29.0%</td>
</tr>
<tr>
<td>AppLovin (APP)</td>
<td>27.5%</td>
<td>27.3%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>內部持股比例</strong></td>
<td><strong>收益增長</strong></td>
</tr>
<tr>
<td>超微計算機 (SMCI)</td>
<td>13.9%</td>
<td>50.7%</td>
</tr>
<tr>
<td>StubHub Holdings (STUB)</td>
<td>14.2%</td>
<td>73.5%</td>
</tr>
<tr>
<td>SES AI (SES)</td>
<td>12%</td>
<td>68.9%</td>
</tr>
<tr>
<td>Niu Technologies (NIU)</td>
<td>37.2%</td>
<td>93.7%</td>
</tr>
<tr>
<td>Credo Technology Group Holding (CRDO)</td>
<td>10.4%</td>
<td>30.7%</td>
</tr>
<tr>
<td>Cloudflare (NET)</td>
<td>10.2%</td>
<td>43.5%</td>
</tr>
<tr>
<td>Bitdeer Technologies Group (BTDR)</td>
<td>33.4%</td>
<td>131.7%</td>
</tr>
<tr>
<td>Atour Lifestyle Holdings (ATAT)</td>
<td>18%</td>
<td>24.4%</td>
</tr>
<tr>
<td>Astera Labs (ALAB)</td>
<td>11.7%</td>
<td>29.0%</td>
</tr>
<tr>
<td>AppLovin (APP)</td>
<td>27.5%</td>
<td>27.3%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 203 stocks from our Fast Growing US Companies With High Insider Ownership screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們快速增長的美國內部持股比例高的公司篩選器中的 203 只股票的完整列表。</p>
</div><p>Let's uncover some gems from our specialized screener.</p>
<div class="lb-trans"><p>讓我們從我們的專業篩選器中發現一些寶藏。</p>
</div><h2>Krystal Biotech (KRYS)</h2>
<div class="lb-trans"><h2>Krystal Biotech (KRYS)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Krystal Biotech, Inc. is a commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing genetic medicines for diseases with high unmet medical needs in the United States, with a market cap of $6.95 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Krystal Biotech, Inc. 是一家商業階段的生物技術公司，專注於發現、開發、製造和商業化針對美國高未滿足醫療需求疾病的基因藥物，市值為 69.5 億美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue of $373.16 million from its segment focused on genetic medicines addressing diseases with significant unmet medical needs in the United States.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司從其專注於基因藥物的細分市場中產生了 3.7316 億美元的收入，針對美國高未滿足醫療需求的疾病。</p>
</div><p><strong>Insider Ownership:</strong> 10.3%</p>
<div class="lb-trans"><p><strong>內部持股比例：</strong> 10.3%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 28.3% p.a.</p>
<div class="lb-trans"><p><strong>收益增長預測：</strong> 每年 28.3%。</p>
</div><p>Krystal Biotech has demonstrated significant growth, with earnings increasing to US$79.37 million in Q3 2025 from US$27.18 million a year ago. The company is advancing its genetic medicines pipeline across various fields, supported by the FDA's platform technology designation for its KB801 eye drop therapy. Despite trading below estimated fair value, Krystal's revenue and earnings are expected to grow faster than the market average, although insider ownership details over recent months are unavailable.</p>
<div class="lb-trans"><p>Krystal Biotech 展示了顯著的增長，收益從一年前的 2718 萬美元增加到 2025 年第三季度的 7937 萬美元。該公司正在推進其基因藥物管線，涵蓋多個領域，得到了 FDA 對其 KB801 眼藥水療法的技術平台認證的支持。儘管交易價格低於估計的公允價值，但 Krystal 的收入和收益預計將快於市場平均水平增長，儘管最近幾個月內部持股的詳細信息尚不可用。</p>
</div><ul>
<li>Get an in-depth perspective on Krystal Biotech's performance by reading our analyst estimates report here.</li>
<li>Our expertly prepared valuation report Krystal Biotech implies its share price may be lower than expected.</li>
</ul>
<div class="lb-trans"><ul>
<li>通過閲讀我們的分析師估計報告，深入瞭解 Krystal Biotech 的表現。</li>
<li>我們精心準備的 Krystal Biotech 估值報告暗示其股價可能低於預期。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0bee3c6e-0bb9-45f2-94da-e22eb8705c98/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/0bee3c6e-0bb9-45f2-94da-e22eb8705c98/chart/earnings-and-revenue-growth"/></p>
<p>KRYS Earnings and Revenue Growth as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 KRYS 收益和收入增長</p>
</div><h2>Hyatt Hotels (H)</h2>
<div class="lb-trans"><h2>凱悦酒店 (H)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Hyatt Hotels Corporation operates as a hospitality company both in the United States and internationally, with a market cap of approximately $14.69 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 凱悦酒店公司在美國及國際上運營，市值約為 146.9 億美元。</p>
</div><p><strong>Operations:</strong> Hyatt's revenue primarily comes from its Owned and Leased segment at $1.24 billion, followed by Management and Franchising at $1.19 billion, and Distribution contributing $974 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 凱悦的收入主要來自其自有和租賃的細分市場，收入為 12.4 億美元，其次是管理和特許經營收入為 11.9 億美元，分銷貢獻為 9.74 億美元。</p>
</div><p><strong>Insider Ownership:</strong> 11.2%</p>
<div class="lb-trans"><p><strong>內部持股比例：</strong> 11.2%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 57.5% p.a.</p>
<div class="lb-trans"><p><strong>收益增長預測：</strong> 每年 57.5%。</p>
</div><p>Hyatt Hotels Corporation is poised for growth, with revenue expected to increase by 17.8% annually, surpassing the US market average. Despite recent insider selling, the company benefits from strong insider ownership and strategic expansions like Hyatt Place Cancun Airport. Its financial position includes a $1.5 billion revolving credit facility and a recent $399.83 million bond issuance at 5.4%. Although currently unprofitable, earnings are projected to grow significantly over the next three years.</p>
<div class="lb-trans"><p>凱悦酒店公司正處於增長階段，預計收入將以每年 17.8% 的速度增長，超過美國市場平均水平。儘管最近有內部人士出售股票，但公司受益於強大的內部持股和戰略擴張，如凱悦機場酒店。其財務狀況包括 15 億美元的循環信貸額度和最近發行的 3.9983 億美元的債券，利率為 5.4%。儘管目前尚未盈利，但預計在未來三年內收益將顯著增長。</p>
</div><ul>
<li>Dive into the specifics of Hyatt Hotels here with our thorough growth forecast report.</li>
<li>Our valuation report here indicates Hyatt Hotels may be overvalued.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏深入瞭解凱悦酒店的具體情況，查看我們的詳細增長預測報告。</li>
<li>我們的估值報告顯示凱悦酒店可能被高估。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/27434017-c144-4ad1-8d3f-aca9ae5c07f4/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/27434017-c144-4ad1-8d3f-aca9ae5c07f4/chart/earnings-and-revenue-growth"/></p>
<p>H Earnings and Revenue Growth as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 H 收益和收入增長</p>
</div><h2>On Holding (ONON)</h2>
<div class="lb-trans"><h2>On Holding (ONON)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> On Holding AG develops and distributes sports products globally, with a market cap of approximately $16.25 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> On Holding AG 在全球開發和分銷運動產品，市值約為 162.5 億美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily from its Athletic Footwear segment, which amounts to CHF 2.88 billion.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司主要從其運動鞋細分市場產生收入，金額為 28.8 億瑞士法郎。</p>
</div><p><strong>Insider Ownership:</strong> 26.3%</p>
<div class="lb-trans"><p><strong>內部持股比例：</strong> 26.3%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 30.1% p.a.</p>
<div class="lb-trans"><p><strong>收益增長預測：</strong> 每年 30.1%。</p>
</div><p>On Holding is experiencing robust growth, with earnings expected to increase by 30.1% annually, outpacing the US market. The company recently reported strong Q3 results, with sales rising to CHF 794.4 million from CHF 635.8 million year-over-year and net income significantly improved at CHF 118.9 million compared to CHF 30.5 million previously. While insider trading activity remains unclear over the past three months, On Holding's strategic financial maneuvers include a shelf registration filing for future securities offerings.</p>
<div class="lb-trans"><p>On Holding 正在經歷強勁增長，預計收益將以每年 30.1% 的速度增長，超過美國市場。該公司最近報告了強勁的第三季度業績，銷售額從去年同期的 6.358 億瑞士法郎上升至 7.944 億瑞士法郎，淨收入顯著改善，從 3050 萬瑞士法郎提高至 1.189 億瑞士法郎。儘管過去三個月內部交易活動仍不明朗，但 On Holding 的戰略財務舉措包括未來證券發行的貨架註冊申請。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in On Holding's earnings growth report.</li>
<li>According our valuation report, there's an indication that On Holding's share price might be on the expensive side.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊探索我們在 On Holding 收益增長報告中的詳細發現。</li>
<li>根據我們的估值報告，On Holding 的股價可能偏高。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/30b460e6-f1a8-445d-9f78-310d4e375cd1/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/30b460e6-f1a8-445d-9f78-310d4e375cd1/chart/ownership-breakdown"/></p>
<p>ONON Ownership Breakdown as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 ONON 持股結構</p>
</div><h2>Turning Ideas Into Actions</h2>
<div class="lb-trans"><h2>將想法轉化為行動</h2>
</div><ul>
<li>Explore the 203 names from our Fast Growing US Companies With High Insider Ownership screener here.</li>
<li>Curious About Other Options? AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏探索我們快速增長的美國內部持股比例高的公司篩選器中的 203 個名稱。</li>
<li>對其他選擇感到好奇？人工智能即將改變醫療保健。這 30 只股票正在從早期診斷到藥物發現方面進行工作。最重要的是 - 它們的市值都在 100 億美元以下 - 現在仍然有機會提前介入。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.</em></p>
<div class="lb-trans"><p>這篇來自 Simply Wall St 的文章是一般性的。<strong>我們提供基於歷史數據和分析師預測的評論，僅使用無偏見的方法，我們的文章並不旨在提供財務建議。</strong> 它不構成買賣任何股票的推薦，也不考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。該分析僅考慮內部人士直接持有的股票，不包括通過其他工具如公司和/或信託實體間接持有的股票。所有預測的收入和收益增長率均以年化（每年）增長率的形式引用，時間範圍為 1-3 年。</p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>用於國防和災難的移動基礎設施</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波機器人技術不是類人型的。它是完全自主的塔，在 30 分鐘內提供 5G、ISR 和雷達，隨時隨地。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一輪合同之前獲取投資者簡報</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>代表 CiTech 贊助</p>
</div>

Krystal Biotech 和另外兩隻增長型股票是內部人士押注的對象